Tim O'Reilly is the founder and CEO of O'Reilly & Associates, thought by many to be the best computer book publisher in the world. O'Reilly also publishes online through the O'Reilly Network (www.oreillynet.com) and hosts conferences on technology topics. Tim is an activist for open source and open standards, and an opponent of software patents and other incursions of new intellectual property laws into the public domain. Tim's long term vision for his company is to help change the world by capturing and transmitting the knowledge of innovators.
Mike Loukides is an editor for O'Reilly & Associates. He is the author of System Performance Tuning and UNIX for FORTRAN Programmers. Mike's interests are system administration, networking, programming languages, and computer architecture. His academic background includes degrees in electrical engineering (B.S.) and English literature (Ph.D.).
Julie Steele is an Editor at O'Reilly currently working on titles related to Python, SQL, PHP, web frameworks and CMS, databases (relational and non-relational), big data and cloud computing, and data visualization. She's also interested in data transparency and open government, and recently completed a master's degree in political science at Rutgers University.
Colin Hill is the president, chairman and co-founder of GNSHealthcare. He brings years of hands-on scientific experience to hisrole, with expertise in the areas of computational physics and systemsbiology.
Colin is a frequent speaker at international scientific and industryconferences and has appeared in numerous publications and televisionsegments including The Wall Street Journal, CNBC Morning Call, Nature,Forbes, Wired, and The Economist. He serves as CEO and Chairman of GNSHealthcare’s parent company Via Science, and chairman of the board ofFina Technologies, a subsidiary of Via Science that appliesnext-generation artificial intelligence technology to real-timefinancial trading. He also serves on the board of directors of AesRx,a biopharmaceutical company dedicated to the development of a newtreatment for sickle cell disease.
In 2004, Colin was named to MIT Technology Review’s TR100 list of thetop innovators in the world under the age of 35. He graduated fromVirginia Tech with a degree in physics and earned master’s degrees inphysics from McGill University and Cornell University.